Nasdaq
$43.80▼ 0.01%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $26.89BShares out 6.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
32- 1d agoRegular26.10.24 00:586-KKey event#●●●#●●●#●●●
GENMAB A/SBullish
Genmab's investigational ADC, rinatabart sesutecan (Rina-S), met its primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival (OS) in the Phase 3 RAINFOL-02 trial for platinum-resistant ovarian cancer. In the ITT population, Rina-S demonstrated a 71% reduction in the risk of disease progression or death compared to chemotherapy. The company plans to engage with global regulatory authorities to discuss the results and potential next steps.…more
$43.80-0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 20:506-KKey event
GENMAB A/S
Genmab announced that worldwide net trade sales of DARZALEX reached USD 4,239 million for the third quarter of 2026. Of this total, USD 2,528 million was generated in the U.S. and USD 1,711 million in the rest of the world. Genmab receives royalties on these worldwide net sales under its exclusive license agreement with Johnson & Johnson.…more
$43.80-0.01%vs prev closeView filingShare - 10.7Regular26.10.08 01:276-KKey event
GENMAB A/S
Genmab A/S held an Extraordinary General Meeting and approved the 2026 remuneration policy for its Board of Directors, resulting in the grant of 5,300 restricted stock units (RSUs). Each RSU, valued at 2,487 DKK per share at the time of grant, will vest after a three-year period.…more
$43.80-0.01%vs prev closeView filingShare
31 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4m agoClosed26.10.25 20:00#●●●#●●●
Genmab Reports Positive Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer…more
Genmab announced encouraging objective response rates for its investigational drug petosemtamab in first- and second-line metastatic colorectal cancer patients. These updated Phase 2 results support the ongoing global Phase 3 clinical development program.…more
$43.80-0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 1d agoClosed26.10.24 20:00
●●●●●●●● ●●●●● ●●●●●●
Genmab and Incyte have entered a clinical trial collaboration to evaluate a combination therapy for patients with KRAS G12D-mutated metastatic colorectal cancer. This early-stage partnership aims to explore the potential of combining their respective investigational agents with standard chemotherapy.…more
$43.80-0.01%vs prev close - 1d agoRegular26.10.24 00:55
●●●●●●●● ●●●●● ●●●●●●
Genmab's investigational drug Rina-S met its primary and secondary endpoints in a Phase 3 trial, showing significant improvements in progression-free and overall survival for ovarian cancer patients. The company plans to discuss these results with global regulatory authorities for potential approval.…more
$43.80-0.01%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report